Market Snapshot

Urinary Tract Infection Therapeutics Market_Image 1

Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Urinary Tract Infection Therapeutics Market

The market is expected to witness a CAGR of 3.5% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of diabetes and kidney stones and the launch of combination drugs.

According to the World Health Organization (WHO), in 1980, around 108 million people had diabetes, and this number increased to 422 million in 2014, while the prevalence of diabetes in adults increased from 4.7%, in 1980, to 8.5%, in 2014. This trend of increment in diabetes prevalence rate among adults is expected to continue during the forecast period. Therefore, with the increasing prevalence of diabetes, the number of cases of urinary tract infection (UTI) increases, which in turn, increases the demand for drugs; thus, driving the global urinary tract infection therapeutics market.
Additionally, the launch of more efficient combination drugs and increasing geriatric population are expected to boost the growth of the urinary tract infection therapeutics market.
However, according to the Center for Education & Research on Therapeutics, over 2 million cases of adverse drug reactions (ADRs) are reported every year, leading to approximately 100,000 deaths.
According to the FDA, it is estimated that, in the United States, each year, over 350,000 ADRs occur in nursing homes alone.
With an increase in the number of cases of ADRs being reported, globally, there is an awareness among the population about the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.
Additionally, the lack of awareness about the prevalence of UTIs in the developing and underdeveloped countries is also restraining the growth of the market.

Scope of the Report

Urinary tract infection (UTI) affects the urinary tract. It is one of the most common bacterial infections, and it is more common in women, as compared to men. UTI is considered as one of the frequent causes of morbidity and mortality, globally.

Drug
		Penicillin and Combinations
		Quinolones
		Cephalosporin
		Azoles and Amphotericin B
		Nitrofurans
		Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)

Indication
		Complicated UTI
		Uncomplicated UTI
		Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)

Geography

North America
	United States
	Canada
	Mexico

Europe
	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe

Asia-Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Middle East & Africa
	GCC
	South Africa
	Rest of Middle East & Africa

South America
	Brazil
	Argentina
	Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Complicated UTIs are Expected to Show Lucrative Growth in the Indication Segment

The prevalence of uncomplicated UTI is significantly higher, as compared to recurring complicated UTI. However, the prevalence of complicated UTI is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases. Overall, the prevalence of complicated UTI is set to increase during the forecast period, mainly owing to the increasing bacterial resistance in UTI cases and rise in recurrence rate for UTI.

Urinary Tract Infection Therapeutics Market_Image 2

To understand key trends, Download Sample Report

North America Dominates the Market and is Expected to do the Same in the Forecast Period

The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for UTIs. In recent events, during a routine checkup for UTI, a woman was observed to be infected by E. coli that showed resistance to the last-resort antibiotic, Colistin. The discovery of Colistin-resistant bacteria was considered a major issue. In addition to that, the CDC, in collaboration with other organizations, developed guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States.

Urinary Tract Infection Therapeutics Market_Image 3

To understand geography trends, Download Sample Report

Competitive Landscape

The urinary tract infection therapeutics market is highly competitive and consists of a number of major players. Companies, like AstraZeneca, Bayer AG, Cipla Inc., GlaxoSmithKline PLC, Merlion Pharma, Novartis AG, and Pfizer, among others, hold the substantial share of the market.

Major Players

* Complete list of players covered available in the table of contents below

Urinary Tract Infection Therapeutics Market_Image 4

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Increasing Prevalence of Diabetes and Kidney Stones
  2. 4.2.2 Launch of Combination Drugs
3. 4.3 Market Restraints
  1. 4.3.1 Adverse Effects Associated with the Use of Medication
  2. 4.3.2 Lack of Awareness in the Developing and Underdeveloped Countries
4. 4.4 Porter's Five Forces Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 Drug
  1. 5.1.1 Penicillin and Combinations
  2. 5.1.2 Quinolones
  3. 5.1.3 Cephalosporin
  4. 5.1.4 Azoles and Amphotericin B
  5. 5.1.5 Nitrofurans
  6. 5.1.6 Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)
2. 5.2 Indication
  1. 5.2.1 Complicated UTI
  2. 5.2.2 Uncomplicated UTI
  3. 5.2.3 Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)
3. 5.3 Geography
  1. 5.3.1 North America
    1. 5.3.1.1 United States
    2. 5.3.1.2 Canada
    3. 5.3.1.3 Mexico
  2. 5.3.2 Europe
    1. 5.3.2.1 Germany
    2. 5.3.2.2 United Kingdom
    3. 5.3.2.3 France
    4. 5.3.2.4 Italy
    5. 5.3.2.5 Spain
    6. 5.3.2.6 Rest of Europe
  3. 5.3.3 Asia-Pacific
    1. 5.3.3.1 China
    2. 5.3.3.2 Japan
    3. 5.3.3.3 India
    4. 5.3.3.4 Australia
    5. 5.3.3.5 South Korea
    6. 5.3.3.6 Rest of Asia-Pacific
  4. 5.3.4 Middle East & Africa
    1. 5.3.4.1 GCC
    2. 5.3.4.2 South Africa
    3. 5.3.4.3 Rest of Middle East & Africa
  5. 5.3.5 South America
    1. 5.3.5.1 Brazil
    2. 5.3.5.2 Argentina
    3. 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 AstraZeneca
  2. 6.1.2 Bayer AG
  3. 6.1.3 Cipla Inc.
  4. 6.1.4 GlaxoSmithKline PLC
  5. 6.1.5 Merlion Pharma
  6. 6.1.6 Novartis AG
  7. 6.1.7 Pfizer
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments